Nemaura Med Inc Stock Price, News & Analysis

Nemaura Medical, Inc. (NMRD) reported its financial results for Q3 2023, highlighting significant developments in its commercialization efforts. Notably, the company announced an initial patient data from the UK NHS Miboko Study, showing a remarkable 100% weight loss success rate among participants.

The company also received its first U.S. purchase order for 5,000 proBEAT™ subscriptions from HealthFleet, valued at $500,000. In January 2023, Nemaura raised approximately $8.4 million through a Registered Direct Offering and Private Placement, strengthening its balance sheet to support its strategic goals in the upcoming year.

Nemaura Medical (NASDAQ: NMRD) has announced that CEO Dr. Faz Chowdhury will join a fireside chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Conference, taking place virtually from February 21 - 24, 2023. The chat is scheduled for February 22, 2023, at 8:30 am ET. Investors can also schedule one-on-one meetings with Dr. Chowdhury during the conference. Nemaura Medical specializes in non-invasive wearable sensors and health tech solutions, including sugarBEAT®, a CE-marked continuous glucose monitor, and proBEAT™, an AI-driven health service.

Nemaura Medical, Inc. (NASDAQ: NMRD) has successfully closed a registered direct offering with two healthcare-focused institutional investors, resulting in the sale of 4,796,206 shares and warrants for a combined purchase price of $1.75 per share. This offering yielded approximately $8.4 million in gross proceeds, intended for working capital and general corporate purposes. The warrants, exercisable at $2.00 per share, are set to expire in five and a half years. The shares are offered under a shelf registration statement that became effective on March 28, 2022. EF Hutton served as the placement agent for this transaction.

Nemaura Medical (NASDAQ: NMRD) announced a definitive agreement to sell 4,796,206 shares and warrants for the same number of shares to U.S. institutional investors, aiming to raise approximately $8.4 million. The offering price is set at $1.75 per share and warrant, with warrants exercisable at $2.00. Expected closing date is January 31, 2023. Proceeds will be allocated for working capital and general corporate purposes. The shares are offered under an SEC shelf registration statement, while the warrants are part of a private placement under the Securities Act. EF Hutton is the sole placement agent for the offering.

Nemaura Medical (NASDAQ: NMRD) announced a partnership with HealthFleet to integrate its proBEAT glucose sensors into the RestoreHealth wellness program, targeting the U.S. market. An initial order for 5,000 subscriptions and 75,000 sensors is valued at $500,000. This program, aimed at improving health outcomes for individuals with type 2 diabetes and obesity, has already shown promising results, including an average 5.1% weight loss over 12 months. The collaboration potentially positions both companies to capitalize on the growing demand for innovative health solutions in a market projected to reach nearly $59 billion by 2025.

Nemaura Medical (NASDAQ: NMRD) announced initial results from its metabolic health program, Miboko, in partnership with the UK's National Health Service (NHS). A pilot study with 30 obese participants showed an average weight loss of 3.7 pounds and a BMI reduction of 0.6 after 10 weeks, with all participants reporting some weight improvement. The program aims to enhance user engagement through a non-invasive glucose sensor and personalized coaching. The study is set to continue for at least one year, with the NHS expected to publish detailed findings.

Nemaura Medical (Nasdaq: NMRD) has announced that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference on January 19, 2023, at 9:15 am EST. Investors can also meet with Dr. Chowdhury during the event by registering through the provided links. Nemaura is recognized for developing non-invasive wearable diagnostics, including sugarBEAT®, a continuous glucose monitor aimed at diabetes management, and proBEAT™, a digital health service utilizing AI. The company targets the growing diabetes, pre-diabetic, and health-tech markets.

Nemaura Medical (Nasdaq: NMRD) will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 on December 7, 2022, at 9:00 AM EST. CEO Dr. Faz Chowdhury will discuss the company's innovative approach to non-invasive wearable diagnostic devices, including its flagship products sugarBEAT® and proBEAT™. These devices target diabetes management and aim to capitalize on the growing health-tech sector, projected to reach $60 billion by 2023. Investors can register for one-on-one meetings during the conference.

Nemaura Medical (Nasdaq: NMRD) has launched patient studies for its Miboko metabolic health program in collaboration with the UK's NHS. Miboko is notable for integrating a non-invasive glucose sensor with a lifestyle app, enabling personalized dietary recommendations aimed at combating obesity and preventing health issues like diabetes. The program targets over 80 million prediabetic individuals in the U.S. and will be marketed to employers, insurers, and consumers. Nemaura's innovations sit within the growing diabetes market, projected to reach nearly $59 billion by 2025.